Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/06/22 | $41,500,000 | Series B |
ARCH Venture Partners Moore Strategic Ventures Northpond Ventures Sands Capital Tao Capital Partners WARF Ventures | undisclosed |
| 01/23/24 | $55,000,000 | Series C |
ARCH Venture Partners Moore Strategic Ventures Northpond Ventures Sands Capital State of Wisconsin Investment Board Tao Invest Venture Investors WARF Ventures | undisclosed |
